Meeting
2019 ASCO Annual Meeting
Oral DNA vaccination targeting VEGFR-2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma, a phase I/II study: NCT03750071.
Authors
Wolfgang Wick
National Center for Tumor Diseases (NCT), UKHD and German Cancer Research Center (DKFZ), Heidelberg, Germany
Wolfgang Wick , Antje Wick , Michael Platten , Olivier L. Chinot , Martin J. Van Den Bent , Frederic Dhermain , Marc Mansour , Lilli Podola , Heinz Lubenau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT03750071
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS2076)
DOI
10.1200/JCO.2019.37.15_suppl.TPS2076
Abstract #
TPS2076
Poster Bd #
262b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
VXM01 phase I study in patients with progressive glioblastoma: Final results.
First Author: Wolfgang Wick
Poster
2019 ASCO Annual Meeting
Interim results of a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM).
First Author: Andrew B. Lassman
Poster
2020 ASCO Virtual Scientific Program
Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM).
First Author: Shiao-Pei S. Weathers
Poster
2018 ASCO Annual Meeting
Preliminary result of phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma (NivoRam study).
First Author: Daisuke Takahari